About Stelis Biopharma
Stelis Biopharma is a company based in Bengaluru (India) founded in 2013 by Sohang Chatterjee was acquired by Strides Pharma Science in September 2019. It operates as a B2B. Stelis Biopharma has raised $201.78 million across 8 funding rounds from investors including Strides Pharma Science, Accel and TPG. The company has 556 employees as of March 31, 2022. Stelis Biopharma offers products and services including Drug-Device Combinations, Sterile Injectables, Complex Biologics, and Soft Gelatin Capsules. Stelis Biopharma operates in a competitive market with competitors including KBI Biopharma, EirGenix, Aldevron, Arranta Bio and Ovagen, among others.
- Headquarter Bengaluru, India
- Employees 556 as on 31 Mar, 2022
- Founders Sohang Chatterjee
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Onesource Specialty Pharma Limited
- Date of Incorporation 12 Jun, 2007
- Jurisdiction Thane, Maharashtra, India
-
Annual Revenue
$16.44 M (USD)506.82as on Mar 31, 2022
-
Net Profit
$-27.97 M (USD)-91.31as on Mar 31, 2022
-
EBITDA
$-11.69 M (USD)-35.48as on Mar 31, 2022
-
Total Equity Funding
$201.78 M (USD)
in 8 rounds
-
Latest Funding Round
$125 M (USD), Series C
Mar 19, 2021
-
Investors
Strides Pharma Science
& 13 more
-
Employee Count
556
as on Mar 31, 2022
-
Acquired by
Strides Pharma Science
(Sep 20, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Stelis Biopharma
Stelis Biopharma offers a comprehensive portfolio of products and services, including Drug-Device Combinations, Sterile Injectables, Complex Biologics, and Soft Gelatin Capsules. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Assembly of drug-device products for pharmaceutical applications.
Development and manufacturing of complex injectable drugs.
Integrated solutions for biologics process and scale-up.
Production of high-quality capsules in various formats.
Unlock access to complete
Unlock access to complete
Funding Insights of Stelis Biopharma
Stelis Biopharma has successfully raised a total of $201.78M across 8 strategic funding rounds. The most recent funding activity was a Series C round of $125 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Series C — $125.0M
-
First Round
First Round
(22 Dec 2007)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2021 | Amount | Series C - Stelis Biopharma | Valuation | TPG | |
| Nov, 2018 | Amount | Series B - Stelis Biopharma | Valuation | Tenshi Life Sciences | |
| Feb, 2016 | Amount | Series B - Stelis Biopharma | Valuation | GMS Holdings |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Stelis Biopharma
Stelis Biopharma has secured backing from 14 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Strides Pharma Science, Accel and TPG. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Fund of funds focused on pre-seed and seed-stage companies
|
Founded Year | Domain | Location | |
|
Investment Firm
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Stelis Biopharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Stelis Biopharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Stelis Biopharma Comparisons
Competitors of Stelis Biopharma
Stelis Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as KBI Biopharma, EirGenix, Aldevron, Arranta Bio and Ovagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of protein formulation, process & cell line development, and cGMP services
|
|
| domain | founded_year | HQ Location |
Biologics development and manufacturing services are offered by EirGenix.
|
|
| domain | founded_year | HQ Location |
Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for microbiome based diseases
|
|
| domain | founded_year | HQ Location |
Provider of germ-free and specific pathogen free production of eggs for vaccine and antibody manufacturing services
|
|
| domain | founded_year | HQ Location |
Vaccines and biologics are developed and manufactured by IDT Biologika.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Stelis Biopharma
Frequently Asked Questions about Stelis Biopharma
When was Stelis Biopharma founded?
Stelis Biopharma was founded in 2013.
Where is Stelis Biopharma located?
Stelis Biopharma is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Is Stelis Biopharma a funded company?
Stelis Biopharma is a funded company, having raised a total of $201.78M across 8 funding rounds to date. The company's 1st funding round was a Series B of $31.15M, raised on Dec 22, 2007.
How many employees does Stelis Biopharma have?
As of Mar 31, 2022, the latest employee count at Stelis Biopharma is 556.
What is the annual revenue of Stelis Biopharma?
Annual revenue of Stelis Biopharma is $16.44M as on Mar 31, 2022.
What does Stelis Biopharma do?
OneSource is a CDMO specializing in pharmaceuticals and biologics, providing end-to-end services from concept to delivery. They operate state-of-the-art facilities in India, focusing on development, manufacturing, and compliance for various modalities like injectables and capsules. With expertise in regulatory approvals and tech transfer, they serve clients in the healthcare sector to transform ideas into market-ready products.
Who are the top competitors of Stelis Biopharma?
Stelis Biopharma's top competitors include KBI Biopharma, Aldevron and Ovagen.
What products or services does Stelis Biopharma offer?
Stelis Biopharma offers Drug-Device Combinations, Sterile Injectables, Complex Biologics, and Soft Gelatin Capsules.
Who are Stelis Biopharma's investors?
Stelis Biopharma has 14 investors. Key investors include Strides Pharma Science, Accel, TPG, RouteOne, and Tenshi Life Sciences.
What is Stelis Biopharma's valuation?
The valuation of Stelis Biopharma is $265.41M as of Mar 2021.